Literature DB >> 30957981

Weight loss induced by deep transcranial magnetic stimulation in obesity: A randomized, double-blind, sham-controlled study.

Anna Ferrulli1, Concetta Macrì1, Ileana Terruzzi2, Stefano Massarini1, Federico Ambrogi3, Michela Adamo1, Valentina Milani4, Livio Luzi1,2.   

Abstract

AIM: To test the hypothesis that deep transcranial magnetic stimulation (dTMS) reduces food craving and causes weight loss via neuromodulation.
MATERIALS AND METHODS: This pilot study was designed as a randomized, double-blind, sham-controlled study. A total of 33 obese people (nine men, 24 women, mean age 48.1 ± 10.6 years, body mass index [BMI] 36.9 ± 4.7 kg/m2 ) were randomized and completed the study: 13 participants underwent a 5-week treatment with high-frequency (HF) dTMS (18 Hz; HF group), 10 were treated with low-frequency (LF) dTMS (1 Hz; LF group), and 10 were sham-treated (sham group). Food craving, and metabolic and neuro-endocrine variables were evaluated at baseline, after the 5-week treatment, and at follow-up visits (1 month, 6 months, 1 year after the end of treatment).
RESULTS: The mixed-model analysis for repeated measures showed a significant interaction of time and groups for body weight (P = 0.001) and BMI (P = 0.001), with a significant body weight (-7.83 ± 2.28 kg; P = 0.0009) and BMI (-2.83 ± 0.83, P = 0.0009) decrease in the HF versus the sham group. A decreasing trend in food craving in the HF versus the LF and sham groups (P = 0.073) was observed. A significant improvement of metabolic and physical activity variables was found (P < 0.05) in the HF group.
CONCLUSIONS: We demonstrated the safety and efficacy of dTMS, in addition to physical exercise and a hypocaloric diet, in reducing body weight for up to 1 year in obese people. We hypothesize that a possible mechanism of HF dTMS treatment is modulation of the dopaminergic pathway and stimulation of physical activity.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  appetite control; obesity therapy; randomised trial; weight control

Year:  2019        PMID: 30957981     DOI: 10.1111/dom.13741

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  6 in total

Review 1.  Electroceuticals in the Gastrointestinal Tract.

Authors:  Khalil B Ramadi; Shriya S Srinivasan; Giovanni Traverso
Journal:  Trends Pharmacol Sci       Date:  2020-10-27       Impact factor: 14.819

2.  Efficacy and acceptability of noninvasive brain stimulation interventions for weight reduction in obesity: a pilot network meta-analysis.

Authors:  Bing-Yan Zeng; Bing-Syuan Zeng; Yen-Wen Chen; Chao-Ming Hung; Cheuk-Kwan Sun; Yu-Shian Cheng; Brendon Stubbs; Andre F Carvalho; Andre R Brunoni; Kuan-Pin Su; Yu-Kang Tu; Yi-Cheng Wu; Tien-Yu Chen; Pao-Yen Lin; Chih-Sung Liang; Chih-Wei Hsu; Ping-Tao Tseng; Cheng-Ta Li
Journal:  Int J Obes (Lond)       Date:  2021-05-10       Impact factor: 5.095

3.  Deep Transcranial Magnetic Stimulation Affects Gut Microbiota Composition in Obesity: Results of Randomized Clinical Trial.

Authors:  Anna Ferrulli; Lorenzo Drago; Sara Gandini; Stefano Massarini; Federica Bellerba; Pamela Senesi; Ileana Terruzzi; Livio Luzi
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

4.  Deep transcranial magnetic stimulation in combination with skin thermography in obesity: a window on sympathetic nervous system.

Authors:  Anna Ferrulli; Sara Gandini; Giulio Cammarata; Veronica Redaelli; Stefano Massarini; Concetta Macrì; Ileana Terruzzi; Daniele Cannavaro; Fabio Luzi; Livio Luzi
Journal:  Acta Diabetol       Date:  2022-02-17       Impact factor: 4.087

5.  Safety and tolerability of repeated sessions of deep transcranial magnetic stimulation in obesity.

Authors:  Anna Ferrulli; Stefano Massarini; Concetta Macrì; Livio Luzi
Journal:  Endocrine       Date:  2020-09-22       Impact factor: 3.633

6.  Reduction of impulsivity in patients receiving deep transcranial magnetic stimulation treatment for obesity.

Authors:  Livio Luzi; Sara Gandini; Stefano Massarini; Federica Bellerba; Ileana Terruzzi; Pamela Senesi; Concetta Macrì; Anna Ferrulli
Journal:  Endocrine       Date:  2021-06-25       Impact factor: 3.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.